277 related articles for article (PubMed ID: 30043247)
21. The Complex Spine in Children with Spinal Muscular Atrophy: The Transforaminal Approach-A Transformative Technique.
Towbin R; Schaefer C; Kaye R; Abruzzo T; Aria DJ
AJNR Am J Neuroradiol; 2019 Aug; 40(8):1422-1426. PubMed ID: 31296522
[TBL] [Abstract][Full Text] [Related]
22. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
[TBL] [Abstract][Full Text] [Related]
24. Spinal muscular atrophy 5Q - Treatment with nusinersen.
; Silvinato A; Bernardo WM
Rev Assoc Med Bras (1992); 2018 Jun; 64(6):484-491. PubMed ID: 30304304
[TBL] [Abstract][Full Text] [Related]
25. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.
Sansone VA; Albamonte E; Salmin F; Casiraghi J; Pirola A; Bettinelli M; Rao F; Mancini L; Tovaglieri N; Fedeli F; Stoia P; Heinen M; Cozzi V; Carraro E; Lunetta C; Di Bari A; Mercuri E;
Neurol Sci; 2019 Feb; 40(2):327-332. PubMed ID: 30430317
[TBL] [Abstract][Full Text] [Related]
26. Pediatric SMA patients with complex spinal anatomy: Implementation and evaluation of a decision-tree algorithm for administration of nusinersen.
Carrera-García L; Muchart J; Lazaro JJ; Expósito-Escudero J; Cuadras D; Medina J; Bosch de Basea M; Colomer J; Jimenez-Mallebrera C; Ortez C; Natera-de Benito D; Nascimento A
Eur J Paediatr Neurol; 2021 Mar; 31():92-101. PubMed ID: 33711792
[TBL] [Abstract][Full Text] [Related]
27. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
[TBL] [Abstract][Full Text] [Related]
28. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
[TBL] [Abstract][Full Text] [Related]
29. Delivery of Nusinersen Through an Ommaya Reservoir in Spinal Muscular Atrophy.
Iannaccone ST; Paul D; Castro D; Weprin B; Swift D
J Clin Neuromuscul Dis; 2021 Mar; 22(3):129-134. PubMed ID: 33595996
[TBL] [Abstract][Full Text] [Related]
30. Computed-tomography-guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations.
Spiliopoulos S; Reppas L; Zompola C; Palaiodimou L; Papadopoulou M; Filippiadis D; Palialexis K; Ploussi A; Efstathopoulos E; Tsivgoulis G; Brountzos E
Eur J Neurol; 2020 Jul; 27(7):1343-1349. PubMed ID: 32250518
[TBL] [Abstract][Full Text] [Related]
31. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
[TBL] [Abstract][Full Text] [Related]
32. Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
Strauss KA; Carson VJ; Brigatti KW; Young M; Robinson DL; Hendrickson C; Fox MD; Reed RM; Puffenberger EG; Mackenzie W; Miller F
J Pediatr Orthop; 2018; 38(10):e610-e617. PubMed ID: 30134351
[TBL] [Abstract][Full Text] [Related]
33. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study.
Acsadi G; Crawford TO; Müller-Felber W; Shieh PB; Richardson R; Natarajan N; Castro D; Ramirez-Schrempp D; Gambino G; Sun P; Farwell W
Muscle Nerve; 2021 May; 63(5):668-677. PubMed ID: 33501671
[TBL] [Abstract][Full Text] [Related]
35. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
[No Abstract] [Full Text] [Related]
36. Nusinersen Administration Via an Intrathecal Port in a 16-Year-Old Spinal Muscular Atrophy Patient with Profound Scoliosis.
Flotats-Bastardas M; Linsler S; Zemlin M; Meyer S
Pediatr Neurosurg; 2020; 55(1):54-57. PubMed ID: 31722365
[TBL] [Abstract][Full Text] [Related]
37. Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections.
Weaver JJ; Hallam DK; Chick JFB; Vaidya S; Shin DS; Natarajan N; Rad N; Reis J; Koo KSH; Shivaram GM; Thibodeau A; Apkon S; Monroe EJ
J Neurointerv Surg; 2021 Jan; 13(1):75-78. PubMed ID: 32471828
[TBL] [Abstract][Full Text] [Related]
38. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
39. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
40. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
